After BioCryst fizzle, a new oral HAE player emerges

A new player in the search for an oral hereditary angioedema pill has received a major boost and show of confidence.

Pharvaris announced $66 million in Series B financing for its B2 receptor antagonist pill, nearly tripling the funding Attune Pharmaceuticals recently received in Series B for its own hereditary angioedema (HAE) pill. The money will fuel the company’s Phase 1 trial on its lead compound, PHAp121, on healthy volunteers. The first subjects have already been dosed.